Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 6Lymphoma, Large-Cell, Immunoblastic 6Hodgkin Disease 6Burkitt Lymphoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Sezary Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Prostatic Neoplasms 4Multiple Myeloma 4Melanoma 4Lung Neoplasms 4Leukemia 4Immunoblastic Lymphadenopathy 4Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Blast Crisis 3

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × tanespimycin × Clear all
NCT00118092 2017-04-18

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT00058253 2014-06-17

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00004065 2013-06-24

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Blast Crisis, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Leukemia, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Esthesioneuroblastoma, Olfactory, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00564928 2012-12-11

IPI-504-04

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡